These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

339 related items for PubMed ID: 25303896

  • 1. New developments in the management of neurogenic orthostatic hypotension.
    Biaggioni I.
    Curr Cardiol Rep; 2014 Nov; 16(11):542. PubMed ID: 25303896
    [Abstract] [Full Text] [Related]

  • 2. Neurogenic orthostatic hypotension in Parkinson's disease: evaluation, management, and emerging role of droxidopa.
    Isaacson SH, Skettini J.
    Vasc Health Risk Manag; 2014 Nov; 10():169-76. PubMed ID: 24729712
    [Abstract] [Full Text] [Related]

  • 3. Defining successful treatment of neurogenic orthostatic hypotension with droxidopa in a patient with multiple system atrophy.
    Goodman BP, Gupta F.
    Clin Auton Res; 2017 Jul; 27(Suppl 1):21-23. PubMed ID: 28631222
    [No Abstract] [Full Text] [Related]

  • 4. Diagnosing and treating neurogenic orthostatic hypotension in primary care.
    Kuritzky L, Espay AJ, Gelblum J, Payne R, Dietrich E.
    Postgrad Med; 2015 Jul; 127(7):702-15. PubMed ID: 26012731
    [Abstract] [Full Text] [Related]

  • 5. Droxidopa in neurogenic orthostatic hypotension.
    Kaufmann H, Norcliffe-Kaufmann L, Palma JA.
    Expert Rev Cardiovasc Ther; 2015 Jul; 13(8):875-91. PubMed ID: 26092297
    [Abstract] [Full Text] [Related]

  • 6. Randomized withdrawal study of patients with symptomatic neurogenic orthostatic hypotension responsive to droxidopa.
    Biaggioni I, Freeman R, Mathias CJ, Low P, Hewitt LA, Kaufmann H, Droxidopa 302 Investigators.
    Hypertension; 2015 Jan; 65(1):101-7. PubMed ID: 25350981
    [Abstract] [Full Text] [Related]

  • 7. Integrated analysis of droxidopa trials for neurogenic orthostatic hypotension.
    Biaggioni I, Arthur Hewitt L, Rowse GJ, Kaufmann H.
    BMC Neurol; 2017 May 12; 17(1):90. PubMed ID: 28494751
    [Abstract] [Full Text] [Related]

  • 8. Effectiveness of droxidopa compared to midodrine in standing blood pressure and orthostatic tolerance in adults with neurogenic orthostatic hypotension: a systematic review protocol.
    Patrick K, Martin T.
    JBI Database System Rev Implement Rep; 2017 Sep 12; 15(9):2287-2294. PubMed ID: 28902695
    [Abstract] [Full Text] [Related]

  • 9. Adding droxidopa to fludrocortisone or midodrine in a patient with neurogenic orthostatic hypotension and Parkinson disease.
    Kremens D, Lew M, Claassen D, Goodman BP.
    Clin Auton Res; 2017 Jul 12; 27(Suppl 1):29-31. PubMed ID: 28674867
    [No Abstract] [Full Text] [Related]

  • 10. Chemical pharmacotherapy for the treatment of orthostatic hypotension.
    Cheshire WP.
    Expert Opin Pharmacother; 2019 Feb 12; 20(2):187-199. PubMed ID: 30376728
    [Abstract] [Full Text] [Related]

  • 11. Adjusting droxidopa for neurogenic orthostatic hypotension in a patient with Parkinson disease.
    Goodman BP, Claassen D, Mehdirad A.
    Clin Auton Res; 2017 Jul 12; 27(Suppl 1):17-19. PubMed ID: 28631223
    [No Abstract] [Full Text] [Related]

  • 12. Droxidopa in patients with neurogenic orthostatic hypotension associated with Parkinson's disease (NOH306A).
    Hauser RA, Hewitt LA, Isaacson S.
    J Parkinsons Dis; 2014 Jul 12; 4(1):57-65. PubMed ID: 24326693
    [Abstract] [Full Text] [Related]

  • 13. Droxidopa for the short-term treatment of symptomatic neurogenic orthostatic hypotension in Parkinson's disease (nOH306B).
    Hauser RA, Isaacson S, Lisk JP, Hewitt LA, Rowse G.
    Mov Disord; 2015 Apr 15; 30(5):646-54. PubMed ID: 25487613
    [Abstract] [Full Text] [Related]

  • 14. Droxidopa: a review of its use in symptomatic neurogenic orthostatic hypotension.
    Keating GM.
    Drugs; 2015 Feb 15; 75(2):197-206. PubMed ID: 25559422
    [Abstract] [Full Text] [Related]

  • 15. Persistent unexplained chest pain and dyspnea in a patient with coronary artery disease: a case report.
    Mobarek SK.
    BMC Cardiovasc Disord; 2020 Feb 04; 20(1):54. PubMed ID: 32019498
    [Abstract] [Full Text] [Related]

  • 16. Droxidopa and Reduced Falls in a Trial of Parkinson Disease Patients With Neurogenic Orthostatic Hypotension.
    Hauser RA, Heritier S, Rowse GJ, Hewitt LA, Isaacson SH.
    Clin Neuropharmacol; 2016 Feb 04; 39(5):220-6. PubMed ID: 27332626
    [Abstract] [Full Text] [Related]

  • 17. Standing and Supine Blood Pressure Outcomes Associated With Droxidopa and Midodrine in Patients With Neurogenic Orthostatic Hypotension: A Bayesian Meta-analysis and Mixed Treatment Comparison of Randomized Trials.
    Chen JJ, Han Y, Tang J, Portillo I, Hauser RA, Dashtipour K.
    Ann Pharmacother; 2018 Dec 04; 52(12):1182-1194. PubMed ID: 29972032
    [Abstract] [Full Text] [Related]

  • 18. Polypharmacy: droxidopa to treat neurogenic orthostatic hypotension in a patient with Parkinson disease and type 2 diabetes mellitus.
    Vernino S, Claassen D.
    Clin Auton Res; 2017 Jul 04; 27(Suppl 1):33-34. PubMed ID: 28674868
    [No Abstract] [Full Text] [Related]

  • 19. Managing neurogenic orthostatic hypotension in a patient presenting with pure autonomic failure who later developed Parkinson disease.
    Gupta F, Kremens D, Vernino S, Karabin B.
    Clin Auton Res; 2017 Jul 04; 27(Suppl 1):9-11. PubMed ID: 28699048
    [No Abstract] [Full Text] [Related]

  • 20. Utility of autonomic testing for the efficient diagnosis and effective pharmacological management of neurogenic orthostatic hypotension.
    Alam SB, Almardini W, Suleman A.
    BMJ Case Rep; 2019 Aug 20; 12(8):. PubMed ID: 31434666
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.